United StatesHealth

Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.

The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.

Viking Therapeutics (NASDAQ:VKTX) finished enrolling patients in a clinical trial designed to test how different dosing schedules of its experimental obesity drug can help people keep weight off, a key step in its bid to compete with established giants in the metabolic space.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive interim data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI in patients with eosinophilic esophagitis.

Watertown, Massachusetts-based Acrivon Therapeutics (NASDAQ:ACRV) provided an interim clinical update across its precision oncology pipeline, highlighted by promising response rates for its lead candidate ACR-368 in an ongoing Phase 2b trial.

Invivyd (NASDAQ:IVVD) reported preliminary fourth-quarter net product revenue of $17.2 million for its COVID-19 antibody, PEMGARDA.

The figure marks a 25% increase over the same period last year and a 31% sequential jump from the third quarter.

NervGen Pharma Corp. (NASDAQ:NGEN) officially began trading on the Nasdaq Stock Market on January 8, marking a transition into a late-stage biopharmaceutical player.

Organon (NYSE:OGN) has entered a strategic agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid), a first-in-class treatment for high cholesterol, across France, Denmark, Iceland, Sweden, Finland, and Norway.

Pharming Group N.V. (NASDAQ:PHAR) reported preliminary, unaudited full-year 2025 revenues of approximately $376 million, topping its own recently elevated guidance and marking a 27% increase over 2024.

Evotec SE (NASDAQ:EVO) announced that its Seattle-based subsidiary, Just – Evotec Biologics, has received a new grant (INV072135) from the Bill & Melinda Gates Foundation to accelerate the development of affordable biologics for low- and middle-income countries.

New US dietary guidelines place protein and whole foods at the centre of federal nutrition policy.

OpenAI’s rollout of ChatGPT Health has raised fresh questions over how sensitive medical data is protected.

Oculis Holding AG (NASDAQ:OCS) is set to showcase its late-stage ophthalmology pipeline at the 44th Annual J.P. Morgan Healthcare Conference on January 14, following a pivotal start to the year.